Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 819093, 7 pages
http://dx.doi.org/10.1155/2014/819093
Research Article

The Influence of Standardized Valeriana officinalis Extract on the CYP3A1 Gene Expression by Nuclear Receptors in In Vivo Model

1Laboratory of Experimental Pharmacogenetics, Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, Marii Magdaleny 14, 61-861 Poznan, Poland
2Department of Quality Control of Medicinal Products and Dietary Supplements, Institute of Natural Fibres and Medicinal Plants, Libelta 27, 61-707 Poznan, Poland
3Department of Rehabilitation, Poznan University of Medical Sciences, 28 Czerwca 1956, 61-545 Poznan, Poland
4Department of Pharmacology, Poznan University of Medical Sciences, Rokietnicka 5a, 60-806 Poznan, Poland
5Department of Pharmacology and Biotechnology, Institute of Natural Fibres and Medicinal Plants, Libelta 27, 61-707 Poznan, Poland
6Department of Pharmaceutical Botany and Plant Biotechnology, Poznan University of Medical Science, Marii Magdaleny 14, 61-861 Poznan, Poland

Received 19 February 2014; Revised 28 August 2014; Accepted 29 August 2014; Published 11 September 2014

Academic Editor: Stelvio M. Bandiera

Copyright © 2014 Anna Bogacz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Stevinson and E. Ernst, “Valerian for insomnia: a systematic review of randomized clinical trials,” Sleep Medicine, vol. 1, no. 2, pp. 91–99, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. A. D. Krystal and I. Ressler, “The use of Valerian in neuropsychiatry,” CNS Spectrums, vol. 6, no. 10, pp. 841–847, 2001. View at Google Scholar · View at Scopus
  3. P. J. Houghton, “The scientific basis for the reputed activity of valerian,” Journal of Pharmacy and Pharmacology, vol. 51, no. 5, pp. 505–512, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Yao, H. E. Ritchie, and P. D. Brown-Woodman, “A developmental toxicity-screening test of valerian,” Journal of Ethnopharmacology, vol. 113, no. 2, pp. 204–209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. V. V. Dunayev, S. D. Trzhetsinsky, V. S. Tishkin, N. S. Fursa, V. I. Linenko, and V. R. Stets, “Biological activity of the sum of valepotriates isolated from Valeriana alliariifolia,” Pharmacology & Toxicology, vol. 50, no. 6, pp. 33–37, 1987. View at Google Scholar · View at Scopus
  6. T. Lefebvre, B. C. Foster, C. E. Drouin et al., “In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 2, pp. 265–273, 2004. View at Google Scholar · View at Scopus
  7. Goodman and Gilman’s, The Pharmacological Basis of Therapeutics. Drug Metabolism, McGraw-Hill, New York, NY, USA, 11th edition, 2006.
  8. T. W. Tam, R. Liu, J. T. Arnason et al., “Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3,” Journal of Ethnopharmacology, vol. 126, no. 1, pp. 119–126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. L. B. Moore, D. J. Parks, S. A. Jones et al., “Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands,” The Journal of Biological Chemistry, vol. 275, no. 20, pp. 15122–15127, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. C. P. Martínez-Jiménez, R. Jover, M. T. Donato, J. V. Castell, and M. J. Gómez-Lechón, “Transcriptional regulation and expression of CYP3A4 in hepatocytes,” Current Drug Metabolism, vol. 8, no. 2, pp. 185–194, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Zhang, Y. Li, and Q. Li, “Inhibition of cytochrome P450 3A in rat liver by the diorganotin (IV) compound di-n-Butyl-di-(4-chlorobenzohydroxamato) tin (IV) and its probable mechanism,” Molecules, vol. 17, no. 9, pp. 10994–11009, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Matsunaga, M. Maruyama, T. Matsubara, K. Nagata, Y. Yamazoe, and S. Ohmori, “Mechanisms of CYP3A induction by glucocorticoids in human fetal liver cells,” Drug Metabolism and Pharmacokinetics, vol. 27, no. 6, pp. 653–657, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Thangavel, E. Boopathi, and B. H. Shapiro, “Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men,” Endocrinology, vol. 152, no. 12, pp. 4813–4824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Honkakoski, I. Zelko, T. Sueyoshi, and M. Negishi, “The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene,” Molecular and Cellular Biology, vol. 18, no. 10, pp. 5652–5658, 1998. View at Google Scholar · View at Scopus
  15. M. E. Wyde, E. Bartolucci, A. Ueda et al., “The environmental pollutant 1,1-Dichloro-2,2-bis (p-chlorophenyl)ethylene induces rat hepatic cytochrome P450 2B and 3A expression through the constitutive androstane receptor and pregnane X receptor,” Molecular Pharmacology, vol. 64, no. 2, pp. 474–481, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Bertilsson, J. Heidrich, K. Svensson et al., “Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 21, pp. 12208–12213, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Lehmann, D. D. McKee, M. A. Watson, T. M. Willson, J. T. Moore, and S. A. Kliewer, “The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions,” Journal of Clinical Investigation, vol. 102, no. 5, pp. 1016–1023, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Negi, M. A. Akbarsha, and R. K. Tyagi, “Clinical correlates in drug-herbal interaction mediatel via nuclear receptor PXR activation and cytochro me P450 induction,” Journal of Endocrinology Reproduction, vol. 12, no. 1, pp. 1–12, 2008. View at Google Scholar
  19. J. L. Harvey, A. J. Paine, P. Maurel, and M. C. Wright, “Effect of the adrenal 11-β-hydroxylase inhibitor metyrapone on human hepatic cytochrome P-450 expression: induction of cytochrome P-450 3A4,” Drug Metabolism and Disposition, vol. 28, no. 1, pp. 96–101, 2000. View at Google Scholar · View at Scopus
  20. L. B. Moore, B. Goodwin, S. A. Jones et al., “St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 13, pp. 7500–7502, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Pavek and Z. Dvorak, “Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues,” Current Drug Metabolism, vol. 9, no. 2, pp. 129–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Adams, “Identification of essential oil components by gas chromatophy/quadrupole mass spectroscopy,” Journal of American Society Mass Spectrometry, vol. 16, no. 11, pp. 1902–1903, 2005. View at Google Scholar
  23. A. Raal, A. Orav, E. Arak, T. Kailas, and M. Müürisepp, “Variation in the composition of the essential oil of Valeriana officinalis L. roots from Estonia,” Proceedings of the Estonian Academy of Sciences: Chemistry, vol. 56, no. 2, pp. 67–74, 2007. View at Google Scholar · View at Scopus
  24. P. M. Mrozikiewicz, A. Bogacz, M. Karasiewicz et al., “The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level,” Phytomedicine, vol. 17, no. 10, pp. 830–833, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. W. Budzinski, B. C. Foster, S. Vandenhoek, and J. T. Arnason, “An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures,” Phytomedicine, vol. 7, no. 4, pp. 273–282, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Sparreboom, M. C. Cox, M. R. Acharya, and W. D. Figg, “Herbal remedies in the United States: potential adverse interactions with anticancer agents,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2489–2503, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Zhou, Y. Gao, W. Jiang, M. Huang, A. Xu, and J. W. Paxton, “Interactions of herbs with cytochrome P450,” Drug Metabolism Reviews, vol. 35, no. 1, pp. 35–98, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. J. L. Donovan, C. L. DeVane, K. D. Chavin et al., “Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers,” Drug Metabolism and Disposition, vol. 32, no. 12, pp. 1333–1336, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. B. J. Gurley, S. F. Gardner, M. A. Hubbard et al., “In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes,” Clinical Pharmacology and Therapeutics, vol. 77, no. 5, pp. 415–426, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. J.-M. Pascussi, L. Drocourt, J.-M. Fabre, P. Maurel, and M.-J. Vilarem, “Dexamethasone induces pregnane X receptor and retinoid X receptor-α expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators,” Molecular Pharmacology, vol. 58, no. 2, pp. 361–372, 2000. View at Google Scholar · View at Scopus